Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617

Journal of Nuclear Medicine

Volumn 58, Issue 2, 2017, Pages 312-319

  Ferdinandus, Justin ^a   Eppard, Elisabeth ^a   Gaertner, Florian C ^a   Kürpig, Stefan ^a   Fimmers, Rolf ^b   Yordanova, Anna ^a   Hauser, Stefan ^a   Feldmann, Georg ^a   Essler, Markus ^a   Ahmadzadehfar, Hojjat ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

177Lu; Prostate cancer; PSA; PSMA; Radioligand therapy; Treatment response

Indexed keywords

ANALGESIC AGENT; C REACTIVE PROTEIN; GALLIUM 68; GALLIUM PROSTATE SPECIFIC MEMBRANE ANTIGEN 11 GA 68; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; LACTATE DEHYDROGENASE; LUTETIUM PROSTATE SPECIFIC MEMBRANE ANTIGEN 617 LU 177; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG; 177LU-PSMA-617; DIPEPTIDE; SINGLE HETEROCYCLIC RINGS; TUMOR MARKER;

ADULT; AGE; AGED; ANEMIA; ARTICLE; BLOOD CELL COUNT; BLOOD TRANSFUSION; BONE METASTASIS; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; DISEASE COURSE; DISTANT METASTASIS; DRUG USE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLEASON SCORE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FUNCTION TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER FUNCTION TEST; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; PATIENT HISTORY OF THERAPY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROTEIN BLOOD LEVEL; RADIOLIGAND THERAPY; RETROSPECTIVE STUDY; THERAPY EFFECT; THROMBOCYTE COUNT; TREATMENT RESPONSE; BLOOD; CARCINOMA; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; REPRODUCIBILITY; SECONDARY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

AGED; BIOMARKERS, TUMOR; CARCINOMA; DIPEPTIDES; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MALE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 85011999538     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.116.178228     Document Type: Article

References (32)

1. Afshar-Oromieh A, Hetzheim H, Kratochwil C, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697-1705.
2. 68Ga]galliumlabelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486-495.
3. 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015;5:114.
4. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016;57:1006-1013.
5. Kratochwil C, Giesel FL, Stefanova M, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617. J Nucl Med. 2016;57:1170-1176.
6. 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer. Clin Nucl Med. 2016;41:522-528.
7. 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis. J Nucl Med. 2016;57:1334-1338.
8. 177Lu-PSMA-DKFZ-617 of castrateresistant metastatic prostate cancer. Oncotarget. 2016;7:12477-12488.
9. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187-1197.
10. Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castrationresistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152-160.
11. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213-223.
12. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147-1154.
13. Kantoff PW, Higano CS, Small EJ, Whitmore JB, Frohlich MW, Schellhammer PF. Re: interdisciplinary critique of sipuleucel-Tas immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst. 2012;104:1107-1109, author reply 1109-1112.
14. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.
15. 68Ga]DOTATOCPET/CT predicts response probability of PRRT in neuroendocrine tumors. Mol Imaging Biol. 2015;17:313-318.
16. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med. 2010;51:1349-1356.
17. Kaemmerer D, Trager T, Hoffmeister M, et al. Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy. Oncotarget. 2015;6:27566-27579.
18. Santoni M, Scarpelli M, Mazzucchelli R, et al. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises. J Biol Regul Homeost Agents. 2014;28:555-563.
19. Bensalah K, Leray E, Fergelot P, et al. Prognostic value of thrombocytosis in renal cell carcinoma. J Urol. 2006;175:859-863.
20. Gakis G, Todenhofer T, Stenzl A. The prognostic value of hematological and systemic inflammatory disorders in invasive bladder cancer. Curr Opin Urol. 2011;21:428-433.
21. Yu M, Liu L, Zhang BL, et al. Pretreatment thrombocytosis as a prognostic factor in women with gynecologic malignancies: a meta-analysis. Asian Pac J Cancer Prev. 2012;13:6077-6081.
22. Gücer F, Tamussino K, Keil F, Balkanli-Kaplan P, Yuce MA. Thrombocytosis in gynecologic malignancies. Anticancer Res. 2004;24:2053-2059.
23. Stone RL, Nick AM, McNeish IA, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366:610-618.
24. Voutsadakis IA. Thrombocytosis as a prognostic marker in gastrointestinal cancers. World J Gastrointest Oncol. 2014;6:34-40.
25. Taucher S, Salat A, Gnant M, et al. Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb Haemost. 2003;89:1098-1106.
26. Stravodimou A, Voutsadakis IA. Pretreatment thrombocytosis as a prognostic factor in metastatic breast cancer. Int J Breast Cancer. 2013;2013:289563.
27. Pearlstein E, Ambrogio C, Karpatkin S. Effect of antiplatelet antibody on the development of pulmonary metastases following injection of CT26 colon adenocarcinoma, Lewis lung carcinoma, and B16 amelanotic melanoma tumor cells into mice. Cancer Res. 1984;44:3884-3887.
28. Karpatkin S, Pearlstein E. Role of platelets in tumor cell metastases. Ann Intern Med. 1981;95:636-641.
29. Honn KV, Tang DG, Crissman JD. Platelets and cancer metastasis: a causal relationship? Cancer Metastasis Rev. 1992;11:325-351.
30. Zabrenetzky VS, Kohn EC, Roberts DD. Suramin inhibits laminin-and thrombospondin-mediated melanoma cell adhesion and migration and binding of these adhesive proteins to sulfatide. Cancer Res. 1990;50:5937-5942.
31. Francis JL, Biggerstaff J, Amirkhosravi A. Hemostasis and malignancy. Semin Thromb Hemost. 1998;24:93-109.
32. Hejna M, Raderer M, Zielinski CC. Inhibition of metastases by anticoagulants. J Natl Cancer Inst. 1999;91:22-36.